$ATYR
aTyr Pharma Inc

2016 Q3 Form 10-Q Financial Statement

#000156459017023776 Filed on November 14, 2017

View on sec.gov

Income Statement

Concept 2016 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.470M
YoY Change -2.8%
% of Gross Profit
Research & Development $10.40M
YoY Change 34.32%
% of Gross Profit
Depreciation & Amortization $220.0K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $13.87M
YoY Change 22.56%
Operating Profit -$13.87M
YoY Change 22.56%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $46.00K
YoY Change -387.5%
Pretax Income -$13.82M
YoY Change 21.98%
Income Tax
% Of Pretax Income
Net Earnings -$13.82M
YoY Change 21.98%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$8.178M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.53M
YoY Change -35.17%
Cash & Equivalents $34.33M
Short-Term Investments $36.20M
Other Short-Term Assets $3.100M
YoY Change 19.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $73.60M
YoY Change -33.92%
LONG-TERM ASSETS
Property, Plant & Equipment $1.596M
YoY Change -13.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $10.30M
YoY Change -63.21%
Other Assets $353.0K
YoY Change 157.66%
Total Long-Term Assets $12.33M
YoY Change -58.9%
TOTAL ASSETS
Total Short-Term Assets $73.60M
Total Long-Term Assets $12.33M
Total Assets $85.93M
YoY Change -39.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.565M
YoY Change 124.21%
Accrued Expenses $5.500M
YoY Change 54.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $2.600M
YoY Change -21.21%
Total Short-Term Liabilities $11.90M
YoY Change 35.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.90M
Total Long-Term Liabilities $0.00
Total Liabilities $11.90M
YoY Change 27.12%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.00M
YoY Change
Total Liabilities & Shareholders Equity $85.90M
YoY Change -39.24%

Cashflow Statement

Concept 2016 Q3
OPERATING ACTIVITIES
Net Income -$13.82M
YoY Change 21.98%
Depreciation, Depletion And Amortization $220.0K
YoY Change 0.0%
Cash From Operating Activities -$14.69M
YoY Change 55.29%
INVESTING ACTIVITIES
Capital Expenditures -$60.00K
YoY Change -84.62%
Acquisitions
YoY Change
Other Investing Activities $6.750M
YoY Change -11.42%
Cash From Investing Activities $6.690M
YoY Change -7.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -860.0K
YoY Change 8.86%
NET CHANGE
Cash From Operating Activities -14.69M
Cash From Investing Activities 6.690M
Cash From Financing Activities -860.0K
Net Change In Cash -8.860M
YoY Change 194.35%
FREE CASH FLOW
Cash From Operating Activities -$14.69M
Capital Expenditures -$60.00K
Free Cash Flow -$14.63M
YoY Change 61.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
2000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
278832000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
552000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3649000
us-gaap Accretion Expense
AccretionExpense
133000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-113000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-18693000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34332000
life Noncash Or Part Noncash Private Placement Issuance Costs Included In Accounts Payable And Accrued Expenses
NoncashOrPartNoncashPrivatePlacementIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
90000
life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-130000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-32058000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-41166000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-24107000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
24925000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
42487000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2547000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
47542000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2452000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Our consolidated financial statements are prepared in accordance with GAAP. The preparation of our consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. The most significant estimates in our consolidated financial statements relate to the fair value of equity issuances and awards, and clinical trials and research and development expense accruals. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p></div>
CY2017Q3 life Cash And Cash Equivalents And Available For Sale Investments
CashAndCashEquivalentsAndAvailableForSaleInvestments
90400000
CY2017Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
175
CY2016Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
21871
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
4607
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22856669
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22856669
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4420665
CY2017Q3 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
18
life Available For Sale Securities In Gross Unrealized Loss Position Maturities Term Maximum
AvailableForSaleSecuritiesInGrossUnrealizedLossPositionMaturitiesTermMaximum
P12M
us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
The first tranche of $10.0 million was funded on November 18, 2016 (Term A Loan). Under the Term A Loan, we received cash proceeds of $7.3 million, net of a $2.6 million repayment of the principal, accrued interest and the $0.5 million final payment under our previous $10.0 million loan and security agreement with SVB (SVB Loan). We did not pay any termination or other fees in connection with the repayment of amounts due under the SVB Loan
CY2017Q1 life Lease Agreement Extended Term
LeaseAgreementExtendedTerm
P2Y
CY2017Q1 life Noncancelable Operating Leases Term Of Extension
NoncancelableOperatingLeasesTermOfExtension
2019-05
CY2017Q2 life Additional Lease Facility
AdditionalLeaseFacility
7411
CY2017Q2 life Noncancelable Operating Leases Term Of Extension
NoncancelableOperatingLeasesTermOfExtension
2019-05
CY2017Q2 life Noncancelable Operating Leases Additional Commitment
NoncancelableOperatingLeasesAdditionalCommitment
700000
CY2017Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1108000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
272000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
420000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1800000
CY2017Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
24161061
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.98
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1189000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1224000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4014988
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1041619
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
32221
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
327971
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4696415
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.73
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.27
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.99

Files In Submission

Name View Source Status
0001564590-17-023776-index-headers.html Edgar Link pending
0001564590-17-023776-index.html Edgar Link pending
0001564590-17-023776.txt Edgar Link pending
0001564590-17-023776-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
life-10q_20170930.htm Edgar Link pending
life-20170930.xml Edgar Link completed
life-20170930.xsd Edgar Link pending
life-20170930_cal.xml Edgar Link unprocessable
life-20170930_def.xml Edgar Link unprocessable
life-20170930_lab.xml Edgar Link unprocessable
life-20170930_pre.xml Edgar Link unprocessable
life-ex104_391.htm Edgar Link pending
life-ex105_390.htm Edgar Link pending
life-ex311_28.htm Edgar Link pending
life-ex312_27.htm Edgar Link pending
life-ex321_25.htm Edgar Link pending
life-ex322_26.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending